Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Gap Down – Should You Sell?

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) gapped down prior to trading on Monday . The stock had previously closed at $25.36, but opened at $24.07. Damora Therapeutics, Inc. Common Stock shares last traded at $26.86, with a volume of 15,596 shares.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on DMRA. UBS Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They set a “buy” rating and a $45.00 target price on the stock. Evercore assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 target price on the stock. Royal Bank Of Canada assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They set an “outperform” rating and a $40.00 target price on the stock. Leerink Partners assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Wednesday, January 7th. They set an “outperform” rating and a $46.00 target price on the stock. Finally, Lifesci Capital upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.40.

Damora Therapeutics, Inc. Common Stock Trading Down 0.7%

The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -2.04 and a beta of 1.50. The stock’s fifty day simple moving average is $26.42 and its 200-day simple moving average is $23.40.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of large investors have recently modified their holdings of the company. Ikarian Capital LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $6,574,000. Janus Henderson Group PLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $40,000. Boothbay Fund Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $2,204,000. Jain Global LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $2,774,000. Finally, Remedium Capital Partners LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $2,772,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.